Corbus Pharmaceuticals (CRBP) Competitors $8.18 -0.10 (-1.21%) Closing price 04:00 PM EasternExtended Trading$8.24 +0.06 (+0.79%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CRBP vs. UPB, ATXS, AURA, PHAT, CMRX, ORKA, ATAI, RVNC, PRME, and ESPRShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Upstream Bio (UPB), Astria Therapeutics (ATXS), Aura Biosciences (AURA), Phathom Pharmaceuticals (PHAT), Chimerix (CMRX), Oruka Therapeutics (ORKA), Atai Life Sciences (ATAI), Revance Therapeutics (RVNC), Prime Medicine (PRME), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Corbus Pharmaceuticals vs. Upstream Bio Astria Therapeutics Aura Biosciences Phathom Pharmaceuticals Chimerix Oruka Therapeutics Atai Life Sciences Revance Therapeutics Prime Medicine Esperion Therapeutics Upstream Bio (NASDAQ:UPB) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts rate UPB or CRBP? Upstream Bio presently has a consensus target price of $56.50, indicating a potential upside of 599.86%. Corbus Pharmaceuticals has a consensus target price of $61.38, indicating a potential upside of 657.90%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the MarketBeat Community believe in UPB or CRBP? Corbus Pharmaceuticals received 447 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 66.91% of users gave Corbus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUpstream BioOutperform Votes4100.00% Underperform VotesNo VotesCorbus PharmaceuticalsOutperform Votes45166.91% Underperform Votes22333.09% Is UPB or CRBP more profitable? Upstream Bio's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Corbus Pharmaceuticals N/A -42.28%-32.92% Does the media refer more to UPB or CRBP? In the previous week, Corbus Pharmaceuticals had 7 more articles in the media than Upstream Bio. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 0 mentions for Upstream Bio. Corbus Pharmaceuticals' average media sentiment score of 0.20 beat Upstream Bio's score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Upstream Bio Neutral Corbus Pharmaceuticals Neutral Which has better earnings & valuation, UPB or CRBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream BioN/AN/AN/AN/AN/ACorbus PharmaceuticalsN/AN/A-$44.60M-$4.69-1.73 Do institutionals and insiders believe in UPB or CRBP? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryCorbus Pharmaceuticals beats Upstream Bio on 9 of the 12 factors compared between the two stocks. Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.63M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.746.1326.4618.82Price / SalesN/A312.32457.0180.82Price / CashN/A67.8344.0437.47Price / Book-5.246.747.634.64Net Income-$44.60M$138.11M$3.18B$245.69M7 Day Performance-3.88%-2.02%-1.82%-2.63%1 Month Performance-31.43%-1.54%0.22%-2.37%1 Year Performance-69.87%-3.14%17.49%13.65% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals4.0441 of 5 stars$8.18-1.2%$61.38+650.3%-64.3%$99.63MN/A-1.7440Analyst ForecastUPBUpstream BioN/A$7.60+3.7%$56.50+643.4%N/A$407.36MN/A0.0038ATXSAstria Therapeutics1.9925 of 5 stars$7.06+0.6%$25.67+263.6%-51.1%$398.40MN/A-3.3830AURAAura Biosciences3.3662 of 5 stars$7.95+0.1%$23.00+189.3%-11.8%$397.11MN/A-4.6050High Trading VolumePHATPhathom Pharmaceuticals2.5178 of 5 stars$5.77+2.7%$23.00+298.6%-45.5%$394.55M$680,000.00-1.01110Gap UpCMRXChimerix4.264 of 5 stars$4.38-3.9%$8.50+94.1%+323.8%$393.94M$320,000.00-4.6690Analyst ForecastAnalyst RevisionNews CoverageORKAOruka Therapeutics2.6538 of 5 stars$11.18-2.2%$39.86+256.5%N/A$391.30MN/A-1.79N/AGap DownATAIAtai Life Sciences3.2748 of 5 stars$2.30+1.3%$9.00+291.3%+1.5%$385.94M$310,000.00-2.8480Insider TradeGap UpHigh Trading VolumeRVNCRevance Therapeutics4.1953 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500PRMEPrime Medicine2.5229 of 5 stars$2.84+9.2%$13.13+362.1%-61.0%$372.49MN/A-1.39234ESPREsperion Therapeutics4.4382 of 5 stars$1.86-0.5%$6.75+262.9%-31.0%$366.49M$116.33M-2.91200 Related Companies and Tools Related Companies UPB Alternatives ATXS Alternatives AURA Alternatives PHAT Alternatives CMRX Alternatives ORKA Alternatives ATAI Alternatives RVNC Alternatives PRME Alternatives ESPR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRBP) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBP Stock Alerts